Fig. 2: Cytotoxicity screening reveals DDR and cell cycle inhibitors are effective in inducing cell death in ATM- or TP53-mutated MCL. | Blood Cancer Journal

Fig. 2: Cytotoxicity screening reveals DDR and cell cycle inhibitors are effective in inducing cell death in ATM- or TP53-mutated MCL.

From: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations

Fig. 2

MCL cell lines were treated with a two-fold serial dilution of a PARP inhibitor AZD2281, b ATR inhibitor AZD6738, c p53 reactivator APR-246, or d CDK4/6 inhibitor abemaciclib for 3 days and the viability were evaluated using CellTiter-Glo. Similarly, the viability of MCL cells treated with a two-fold serial dilution of e PRMT5 inhibitors GSK3326595 or f LLY-283 for 6 days were evaluated due to longer responding time required for PRMT5 inhibitors. g Viability of primary MCL cells from R/R patients treated with a two-fold serial dilution of PRMT5 inhibitors GSK3326595 for only 3 days. The primary cells stop growing after a few days in culture, therefore we shortened the treatment period.

Back to article page